BioCardia Files 8-K: Regulation FD & Financials
Ticker: BCDA · Form: 8-K · Filed: Jul 25, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, regulation-fd
Related Tickers: BCDA
TL;DR
BioCardia dropped an 8-K on July 25th covering Reg FD and financials. Check it out.
AI Summary
On July 25, 2024, BioCardia, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and operates in the Biological Products sector.
Why It Matters
This filing provides crucial updates on BioCardia's regulatory compliance and financial reporting, which are important for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard disclosures and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- July 25, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 25, 2024.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What was a previous name of BioCardia, Inc.?
A previous name of BioCardia, Inc. was Tiger X Medical, Inc.
What is BioCardia, Inc.'s Standard Industrial Classification code?
BioCardia, Inc.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-07-25 07:00:14
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240725_8k.htm (8-K) — 28KB
- ex_703082.htm (EX-99.1) — 16KB
- 0001437749-24-023412.txt ( ) — 194KB
- bcda-20240725.xsd (EX-101.SCH) — 4KB
- bcda-20240725_def.xml (EX-101.DEF) — 13KB
- bcda-20240725_lab.xml (EX-101.LAB) — 17KB
- bcda-20240725_pre.xml (EX-101.PRE) — 13KB
- bcda20240725_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 25, 2024, BioCardia, Inc. (the "Company") issued a press release announcing that patient enrollment has commenced in the pivotal Phase III trial of the CardiAMP Cell Therapy for the treatment of chronic ischemic heart failure of reduced ejection fraction. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated July 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: July 25, 2024